Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BACE1 | P56817 | 4/20 | 0.66 |
| ▸ | SLC6A4 | P31645 | 7/20 | 0.39 |
| ▸ | SLC6A2 | P23975 | 6/20 | 0.39 |
| ▸ | SLC6A3 | Q01959 | 6/20 | 0.39 |
| ▸ | KCNH2 | Q12809 | 4/20 | 0.35 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.34 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4150737 | 0.80 | BACE1 (1.00) | BACE1SLC6A4SLC6A2SLC6A3KCNH2 | |
| SCHEMBL4141478 | 0.79 | BACE1 (0.62) | BACE1SLC6A4SLC6A2SLC6A3 | |
| SCHEMBL4134653 | 0.76 | BACE1 (0.66) | BACE1SLC6A4SLC6A2SLC6A3 | |
| SCHEMBL4140687 | 0.68 | BACE1 (0.78) | BACE1 | |
| SCHEMBL8202810 | 0.62 | SLC6A4 (0.45) | SLC6A4SLC6A2SLC6A3KCNH2CYP2D6 | |
| SCHEMBL4146842 | 0.61 | BACE1 (1.00) | BACE1 | |
| SCHEMBL13904519 | 0.61 | SLC6A4 (0.54) | BACE1SLC6A4SLC6A2SLC6A3 | |
| SCHEMBL4151589 | 0.59 | BACE1 (0.69) | BACE1SLC6A4SLC6A2SLC6A3 | |
| SCHEMBL6950674 | 0.59 | BACE1 (0.45) | BACE1SLC6A4SLC6A2SLC6A3 | |
| SCHEMBL4136824 | 0.59 | BACE1 (1.00) | BACE1SLC6A4SLC6A2SLC6A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090221579-A1 | Substituted Amino-Compounds and Uses Thereof | ASTEX THERAPEUTICS (GB) | 2009-09-03 | — | — | US | disclosed |
| US-20090062282-A1 | Substituted Amino-Pyrimidones and Uses Thereof | ASTRAZENECA AB (SE) | 2009-03-05 | — | — | US | disclosed |
| EP-1802587-A1 | SUBSTITUTED AMINO-COMPOUNDS AND USES THEREOF | AstraZeneca AB (SE) | 2007-07-04 | — | — | EP | disclosed |
| WO-2006041404-A1 | SUBSTITUTED AMINO-COMPOUNDS AND USES THEREOF | ASTRAZENECA AB (SE) | 2006-04-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090221579-A1 | Substituted Amino-Compounds and Uses Thereof | APP, PSEN1, BACE1 | BACE1 3/4885SLC6A4 307/4885SLC6A2 179/4885 |
| US-20090062282-A1 | Substituted Amino-Pyrimidones and Uses Thereof | APP, PSEN1, PSEN2 | BACE1 4/4885SLC6A4 397/4885SLC6A2 206/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.